TRAVERE THERAPEUTICS INC (TVTX:NASDAQ)
$66.17 -1.34 (-1.9849%)
Analysed TRAVERE THERAPEUTICS INC (TVTX:NASDAQ) News Sources
Travere Therapeutics (TVTX) Reports Q2 Loss, Beats Revenue Estimates
04-08-2026
yahoo.com
Travere Therapeutics Q2 Earnings Call Highlights
05-08-2026
marketbeat.com
Travere Therapeutics (TVTX) On Q2 Results And FILSPARI Hopes As Fair Value Stays In View
07-08-2026
yahoo.com
Why Travere Therapeutics (TVTX) Is Up 9.0% After FILSPARI-Driven Q2 Revenue Jump And Wider Loss
07-08-2026
yahoo.com
Travere Therapeutics (TVTX) Q2 2026 Earnings Call Transcript
12-08-2026
fool.com
Travere Therapeutics Sees FILSPARI FSGS Launch Top Expectations, Expands Renal Pipeline
18-08-2026
marketbeat.com
Three Biotech Stocks Stick Out With Their Stellar Charts
21-08-2026
yahoo.com
IBD Stock Of The Day, Travere Therapeutics, Tests Another Breakout. Can The Stock Get Any 'Sweeter?'
21-08-2026
yahoo.com
Travere Therapeutics' Outlook Brightens As Turnaround Looms
08-09-2026
yahoo.com
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11-09-2026
yahoo.com
What is the current price of TRAVERE THERAPEUTICS INC (TVTX:NASDAQ)?
The current price of TRAVERE THERAPEUTICS INC (TVTX:NASDAQ) is $66.17.
TRAVERE THERAPEUTICS INC (TVTX:NASDAQ) absolute price change since previous trading day?
The absolute price change of TRAVERE THERAPEUTICS INC (TVTX:NASDAQ) since the previous trading day is $-1.34.
TRAVERE THERAPEUTICS INC (TVTX:NASDAQ) percentage price change since previous trading day?
The percentage price change of TRAVERE THERAPEUTICS INC (TVTX:NASDAQ) since the previous trading day is -1.9849%.
What is the most recent average sentiment score for TRAVERE THERAPEUTICS INC (TVTX:NASDAQ)?
The most recent average sentiment score for TRAVERE THERAPEUTICS INC (TVTX:NASDAQ) is 78 out of 100.
What is the most recent average sentiment for TRAVERE THERAPEUTICS INC (TVTX:NASDAQ)?
The most recent sentiment for TRAVERE THERAPEUTICS INC (TVTX:NASDAQ) is .
SEC-8K** Filing Available For TRAVERE THERAPEUTICS INC (TVTX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.